Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $0.9073
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 15, 26 |
| HC Wainwright & Co. |
| upgrade |
| Neutral |
| Buy |
| Aug 12, 26 | William Blair | downgrade | Outperform | Market Perform |
| Jun 3, 26 | Craig-Hallum | downgrade | Buy | Hold |
| Jun 1, 26 | TD Cowen | downgrade | Buy | Hold |
| Jun 1, 26 | HC Wainwright & Co. | downgrade | Buy | Neutral |
| Feb 25, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Jan 28, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 6, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 9, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 33.48 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 14.92 | Oscillator | Buy |
| Williams %R (14) | -90.25 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.07 (Hist -0.02) | Oscillator | Strong Sell |
| Average Directional Index (14) | 25.46 (+DI 13.8 / -DI 26.4) | Trend | Strong Sell |
| EMA 20 | 1.02 | MA | Strong Sell |
| SMA 20 | 1.04 | MA | Strong Sell |
| EMA 50 | 1.08 | MA | Strong Sell |
| SMA 50 | 1.08 | MA | Strong Sell |
| SMA 200 | 1.49 | MA | Strong Sell |
Stock news · updated daily
SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia (CMML). “CMML remains a difficult-to-treat hematologic malignancy with limited treatment options for patients, and 40-50% of myeloproliferative CMML1 patients harbor RAS-pathway mutations, which are associated with more aggressive disease,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology.
Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and Cardiff Oncology (NASDAQ: CRDF - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Insider and Institutional Ownership 80.0% of
SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l.
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences.
Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -0.12 | -0.14 | Miss -17.0% | $104.0K |
| May 14, 2026 | -0.13 | -0.18 | Miss -38.5% | $41.00K |
| Feb 24, 2026 | -0.18 | -0.11 | Beat 38.9% | $243.0K |
| Nov 6, 2025 | -0.20 | -0.17 | Beat 15.0% | $120.0K |
| Jul 29, 2025 | -0.19 | -0.21 | Miss -10.5% | $121.0K |
| May 8, 2025 | -0.19 | -0.20 | Miss -5.3% | $109.0K |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jul 14, 26 | Pace Gary W | director | P-Purchase | 687,285 @ $1.46 | $1000.0K |
| Jul 14, 26 | Pace Gary W | director | P-Purchase | 687,285 @ $1.33 | $914.1K |
| Jul 14, 26 | Mohindru Mani | director, officer: Chief Executive Officer | P-Purchase | 34,364 @ $1.46 | $50.00K |
| Jul 14, 26 | Mohindru Mani | director, officer: Chief Executive Officer | P-Purchase | 34,364 @ $1.33 | $45.70K |
| Jun 18, 26 | Mohindru Mani | director, officer: Chief Executive Officer | P-Purchase | 24,703 @ $1.21 | $29.89K |
| Jun 18, 26 | Pace Gary W | director | P-Purchase | 30,000 @ $1.22 | $36.60K |
| Jun 11, 26 | Armitage James O | director | A-Award | 40,565 @ $1.59 | $64.50K |
| Jun 11, 26 | White Lale | director | A-Award | 40,565 @ $1.59 | $64.50K |
TTM vs. 5-year historical average (annual ratios)
| Metric | CRDF | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.5x | -4.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -1.6x | EPS est. -0.58 | In line |
| Price / Book | 2.3x | 2.0x | Elevated |
| Price / Sales | 138.9x | 313.3x | Discount |
| EV / EBITDA | -1.6x | -3.6x | Discount |
| Return on equity | -103.1% | — | Weak |
| Gross margin | 100.0% | 100.0% | In line |
| Debt / Equity | 0.02 | 0.02 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -15.66 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 22, 2026 | 2026-10-22 16:30:15 | View |
| 8-K | Sep 14, 2026 | 2026-09-14 09:28:02 | View |
| DEFA14A | Aug 26, 2026 | 2026-08-26 16:05:02 | View |
| DEF 14A | Aug 26, 2026 | 2026-08-26 16:01:02 | View |
| PRE 14A | Aug 14, 2026 | 2026-08-14 16:01:02 | View |
| 8-K | Aug 11, 2026 | 2026-08-11 16:11:16 | View |
| 10-Q | Aug 11, 2026 | 2026-08-11 16:01:40 | View |
| SC 13G/A | Jul 27, 2026 | 2026-07-27 16:25:24 | View |
| S-8 | Jul 21, 2026 | 2026-07-21 16:01:25 | View |
| 4 | Jul 16, 2026 | 2026-07-16 16:03:02 | View |
Proxy statement (DEF 14A) disclosures
FY2020 · 10-K disclosure